{"id":"aad3199c0c17","type":"article","url":"https://hartvaat.nl/2024/09/17/sotagliflozine-en-gezondheidsstatus-bij-verslechterend-hartfalen-soloist-whf/","title":"Sotagliflozine en gezondheidsstatus bij verslechterend hartfalen: SOLOIST-WHF","title_en":"Effects of Sotagliflozin on Health Status in Patients With Worsening Heart Failure: Results From SOLOIST-WHF.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["bisoprolol","canagliflozine","empagliflozine"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2024.06.036","source_url":"https://doi.org/10.1016/j.jacc.2024.06.036","authors":["Ankeet S Bhatt","Deepak L Bhatt","Ph Gabriel Steg","Michael Szarek","Christopher P Cannon","Lawrence A Leiter","Darren K McGuire","Julia B Lewis","Matthew C Riddle","Adriaan A Voors","Marco Metra","Lars H Lund","Jeffrey M Testani","Christopher S Wilcox","Michael Davies","Bertram Pitt","Mikhail N Kosiborod"],"significance":7,"published":"2024-09-17","source_date":"2024-09-17","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/digoxine-bij-hartfalen/"],"congress":"","summary_en":"This SOLOIST-WHF analysis showed that sotagliflozin significantly improves health status (symptoms, function, quality of life) in patients with worsening heart failure and diabetes, complementing the hard clinical endpoints with patient-centered outcomes.","created":"2026-07-03T10:31:10Z","updated":"2026-07-03T13:30:12Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Analyse van SOLOIST-WHF toonde dat sotagliflozine de gezondheidsstatus significant verbeterde bij patiënten met verslechterend hartfalen. Het duale SGLT1/SGLT2-remmende effect biedt additionele voordelen boven selectieve SGLT2-remming.","abstract_original":"BACKGROUND: Sodium-glucose cotransporter 2 (SGLT2) inhibitors improve health status in heart failure (HF) across the left ejection fraction ejection spectrum. However, the effects of SGLT1 and SGLT2 inhibition on health status are unknown. OBJECTIVES: These prespecified analyses of the SOLOIST-WHF (Effect of Sotagliflozin on Cardiovascular Events in Patients with Type 2 Diabetes Post Worsening Heart Failure) trial examined the effects of sotagliflozin vs placebo on HF-related health status. METHODS: SOLOIST-WHF randomized patients hospitalized or recently discharged after a worsening HF episode to receive sotagliflozin or placebo. The primary endpoint was total number of HF hospitalizations, urgent HF visits, and cardiovascular death. Kansas City Cardiomyopathy Questionnaire-12 (KCCQ-12) score was a prespecified secondary endpoint. This analysis evaluated change in the KCCQ-12 score from baseline to month 4. RESULTS: Of 1,222 patients randomized, 1,113 (91%) had complete KCCQ-12 data at baseline and 4 months. The baseline KCCQ-12 score was low overall (median: 41.7; Q1-Q3: 27.1-58.3) and improved by 4 months in both groups. Sotagliflozin vs placebo reduced the risk of the primary endpoint consistently across KCCQ-12 tertiles (Ptrend = 0.54). Sotagliflozin-treated patients vs those receiving placebo experienced modest improvement in KCCQ-12 at 4 months (adjusted mean change: 4.1 points; 95% CI: 1.3-7.0 points; P = 0.005). KCCQ-12 improvements were consistent across prespecified subgroups, including left ventricular ejection fraction <50% or ≥50%. More patients receiving sotagliflozin vs those receiving placebo had at least small (≥5 points) improvements in KCCQ-12 at 4 months (OR: 1.38; 95% CI: 1.06-1.80; P = 0.017). CONCLUSIONS: Sotagliflozin improved symptoms, physical limitations, and quality of life within 4 months after worsening HF, with consistent benefits across baseline demographic and clinical characteristics. (Effect of Sotagliflozin on Cardiovascular Events in Participants With Type 2 Diabetes Post Worsening Heart Failure [SOLOIST-WHF]; NCT03521934)."}